CA2162854A1 - Method for treating neurological disorders - Google Patents

Method for treating neurological disorders

Info

Publication number
CA2162854A1
CA2162854A1 CA002162854A CA2162854A CA2162854A1 CA 2162854 A1 CA2162854 A1 CA 2162854A1 CA 002162854 A CA002162854 A CA 002162854A CA 2162854 A CA2162854 A CA 2162854A CA 2162854 A1 CA2162854 A1 CA 2162854A1
Authority
CA
Canada
Prior art keywords
neurological disorders
treating neurological
therapeutic agent
cerebro
persist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002162854A
Other languages
French (fr)
Other versions
CA2162854C (en
Inventor
Sinil Kim
Stephen B. Howell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacira Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002162854A priority Critical patent/CA2162854C/en
Priority claimed from PCT/US1993/004645 external-priority patent/WO1994026250A1/en
Publication of CA2162854A1 publication Critical patent/CA2162854A1/en
Application granted granted Critical
Publication of CA2162854C publication Critical patent/CA2162854C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method for ameliorating a neurological disorder in a human by administration to the cerebrospinal fluid (CSF) of a therapeutic agent in a dispersion system which allows the therapeutic agent to persist in the cerebro-ventricular space.
CA002162854A 1993-05-14 1993-05-14 Method for treating neurological disorders Expired - Lifetime CA2162854C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002162854A CA2162854C (en) 1993-05-14 1993-05-14 Method for treating neurological disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002162854A CA2162854C (en) 1993-05-14 1993-05-14 Method for treating neurological disorders
PCT/US1993/004645 WO1994026250A1 (en) 1993-05-14 1993-05-14 Method for treating neurological disorders

Publications (2)

Publication Number Publication Date
CA2162854A1 true CA2162854A1 (en) 1994-11-24
CA2162854C CA2162854C (en) 2003-10-07

Family

ID=29220432

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002162854A Expired - Lifetime CA2162854C (en) 1993-05-14 1993-05-14 Method for treating neurological disorders

Country Status (1)

Country Link
CA (1) CA2162854C (en)

Also Published As

Publication number Publication date
CA2162854C (en) 2003-10-07

Similar Documents

Publication Publication Date Title
CA2310845A1 (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
AU2339792A (en) Treatment of respiratory disorders by nerve stimulation
UA41906C2 (en) Method for treating neurological disorders due to trauma
EP1010431A3 (en) Botulinum toxins for treating pain associated with muscle spasms
CA2100212A1 (en) Use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
AU2674797A (en) Method of treating movement disorders by brain infusion
CA2141436A1 (en) Treatment of Alzheimer's Disease and Modulation of Immune System with Delta-5-Androstenes
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
CA2258895A1 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders
GB2247837B (en) Pharmaceutical product for the treatment of immunoregulatory disorders
AU2800689A (en) Differential delivery of therapeutic agents across the blood brain barrier
EP0730866A3 (en) Treatment of optic nerve disorders with prostanoic acid compounds
GB9212308D0 (en) Therapeutic compositions
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
TW197423B (en)
AU1447095A (en) Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
AU2101288A (en) Taliscanin and other aristolactams for treating neurological disorders, parkinson's disease, alzheimer disease and impotence
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
CA2162854A1 (en) Method for treating neurological disorders
CA2135710A1 (en) Melatonin derivatives for use in treating desynchronization disorders
EP0147185A3 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
IL116828A (en) Use of 3, 4-diphenyl chromans for the preparation of pharmaceutical compositions for the treatment or prophylaxis of cerebral degenerative disorders
EP0273309A3 (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
AU5430894A (en) Diagnosis of eye disorders
EP0784983A3 (en) Use of extracellular hemoglobin

Legal Events

Date Code Title Description
EEER Examination request